Valeant Pharmaceuticals International (NYSE: VRX) may be the big exception in the drug business. Unlike other companies, it isn’t plagued by slow growth, patent issues or development expenses.
Through a...(read more
Valeant Pharmaceuticals’ (VRX) first quarter 2013 earnings of $1.27 (excluding special items but including stock-based compensation expense) were short of the Zacks...(read more
We've seen past commentary from multiple managers on shares of Valeant Pharmaceuticals (VRX) and thought it was worth highlighting given that numerous respected managers own it.
Hedge Fund...(read more